REPCF - RepliCel Life Sciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3786
-0.0006 (-0.1582%)
At close: 2:28PM EDT
Stock chart is not supported by your current browser
Previous Close0.3792
Open0.3823
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3629 - 0.3823
52 Week Range0.2660 - 1.4600
Volume1,046
Avg. Volume12,776
Market Cap7.09M
Beta-1.41
PE Ratio (TTM)-1.03
EPS (TTM)-0.37
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • RepliCel Life Sciences Successfully Closes Financing
    CNW Group3 days ago

    RepliCel Life Sciences Successfully Closes Financing

    RepliCel Life Sciences Successfully Closes Financing

  • Marketwired16 days ago

    Streetwise Reports Interviews CJ Partners' Colin Lee Novick Who Says Japan is Fertile Ground for Biotech Deals

    Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview ...

  • RepliCel Retains Hybrid Financial for Investor Relations
    CNW Grouplast month

    RepliCel Retains Hybrid Financial for Investor Relations

    RepliCel Retains Hybrid Financial for Investor Relations

  • PR Newswirelast month

    RepliCel Retains Hybrid Financial for Investor Relations

    VANCOUVER, Sept. 22, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained Hybrid Financial Inc. ("Hybrid") to provide certain investor relations services (the "Services") to the Company, commencing September 26, 2017. Under the terms of Hybrid's engagement (the "Engagement"), RepliCel has agreed to pay Hybrid a monthly retainer of CAD$15,000 for an initial term of six months, with such retainer payable upon completion of RepliCel's next financing. Upon completion of the initial six-month term, RepliCel may extend the term of the Engagement on a month-to-month basis.

  • PR Newswirelast month

    RepliCel's Partnership Initiatives Mature into Licensing Negotiations

    VANCOUVER, Sept. 13, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it anticipates maturing discussions will lead to one or more new partnership agreements in the near-term. "The release of our positive clinical data earlier this year and the recent unveiling of our next-generation dermal injector prototypes have aggressively bolstered partnership negotiations," says RepliCel President and CEO, R. Lee Buckler. "We remain confident of our ability to execute one or more partnerships for the dermal injector on our way to it being CE-marked by mid-2018, and have also generated significant partnership interest in our biologic assets among strong regional players.

  • CNW Grouplast month

    RepliCel's Partnership Initiatives Mature into Licensing Negotiations

    RepliCel's Partnership Initiatives Mature into Licensing Negotiations

  • PR Newswirelast month

    RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

    VANCOUVER, Sept. 7, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce the timely arrival of its RCI-02 prototypes, which are now ready to be showcased to potential end users and licensing partners. With functioning prototypes in-hand, RepliCel is now engaging with key opinion leaders and clinical dermatologists to solicit feedback critically important to aligning successful early adoption of the device, design clinical studies demonstrating its advantages in select applications, and position the Company for an anticipated successful launch of an approved next-generation dermal injector in the European market next year. "As a practicing dermatologist and a co-founder of RepliCel, I am thrilled to see the functioning prototypes.

  • RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
    CNW Grouplast month

    RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

    RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

  • Marketwired2 months ago

    Streetwise Reports Examines Analyst's View that Cell Therapy Company's Move Decreases Risk

    A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk.Included ...

  • Business Wire2 months ago

    RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

    MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and RepliCel Life Sciences, Inc.  , a regenerative medicine company, today announced that RepliCel has joined MedCision’s ThawSTAR® Early Adopter Program, a novel program that helps companies and investigators de-risk thawing of cell therapies in early stage clinical trials through to commercialization ...

  • PR Newswire2 months ago

    Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

    Q: In your center, a phase 1 trial has been performed to assess the safety of an autologous cell product against skin aging.  Can you tell us why, in your opinion, the data from this trial suggests to you that such a cell treatment has the potential to treat signs of skin aging? Prof. Dr. med Jean Krutmann: I am personally very interested in this approach because it represents, to the best of my knowledge, the first cell-based treatment option for skin aging.

  • Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data
    CNW Group2 months ago

    Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

    Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

  • RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
    PR Newswire4 months ago

    RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

    VANCOUVER, June 13, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company") is pleased to announce it has signed a collaborative research project agreement with the University of British Columbia ("UBC"). The project will be co-lead by the UBC's Dr. Kevin McElwee and Professor Youwen Zhou. The project is designed to deliver a gene and protein expression "map" of healthy hair follicle cells expected to be critically important to improving key components of the manufacturing, regulatory, and clinical profile of RepliCel's cell therapy products.

  • RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
    CNW Group4 months ago

    RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

    RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

  • SmarterAnalyst4 months ago

    Exclusive Interview with RepliCel Life Sciences President and CEO Lee Buckler

    RepliCel Life Sciences Inc. (REPCF) (RP.V) is a biotech company looking not to just treat symptoms, but find cures. RepliCel may have the key, not just to rejuvenated skin and functioning tendons, but also a safe way to stop – and perhaps even reverse - hair loss. This week, I held an interview with President & CEO, Lee Buckler, who spoke with great passion of RepliCel's multi-course trajectory.

  • PR Newswire5 months ago

    RepliCel CEO Provides Company Outlook

    VANCOUVER, May 25, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a regenerative medicine company addressing large-market opportunities with innovative technologies in aesthetics and sports injury/orthopedics, today unveiled its go-forward strategy. In the first few months of 2017, the Company made pivotal announcements based on data collected from all three of its cell therapy programs. Furthermore, RepliCel continues to make significant progress on its nearest-term commercial asset, the dermal injector (RCI-02).

  • CNW Group5 months ago

    RepliCel CEO Provides Company Outlook

    RepliCel CEO Provides Company Outlook

  • United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
    PR Newswire6 months ago

    United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

    With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market VANCOUVER, April 25, 2017 /PRNewswire/ - RepliCel Life Sciences ...

  • United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
    CNW Group6 months ago

    United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

    United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

  • Marketwired6 months ago

    The Life Sciences Report Examines How Positive Trial Results Boost RepliCel's Profile

    Positive results from RepliCel Life Sciences Inc.'s Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon ...

  • Accesswire7 months ago

    RepliCel Life Sciences, a Stem Cell Franchise Meeting Truly Unmet Needs in Medicine

    Clinical Trial in Achilles Tendinosis Passes with Flying Colors BEND, OR / ACCESSWIRE / April 4, 2017 / There's good news for patients suffering from severe heel pain due to a frayed and irritated Achilles ...

  • Positive Results from RepliCel's RCS-01 Phase I Skin Trial are the Company's Most Compelling to Date
    PR Newswire7 months ago

    Positive Results from RepliCel's RCS-01 Phase I Skin Trial are the Company's Most Compelling to Date

    VANCOUVER, April 4, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company") is pleased to report statistically and clinically significant positive data from the interim analysis of its phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin. The primary objective of this trial was to establish a complete safety profile for intradermal injections of RCS-01 (RepliCel's type 1 collagen-expressing, hair follicle-derived fibroblasts ["NBDS cells"]) at six months post-injection. Participants in the Germany-based study did not report any serious adverse events at the interim point of the trial.

  • Zacks Small Cap Research7 months ago

    RepliCel (RP.V) Targeting Multiple Billion Dollar Markets With Autologous Cell Therapies

    RepliCel Life Sciences, Inc. (REPCF) (RP.V) is a regenerative medicine company focused on the use of autologous cell therapies for the treatment of cellular deficits. The company is targeting three potentially multi-billion dollar markets: regenerative hair growth, skin aging, and chronic tendinosis.

  • CNW Group7 months ago

    RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

    RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

  • PR Newswire7 months ago

    RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

    VANCOUVER, March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company") is pleased to report compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel's type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. The clinical trial met its goal of establishing a complete safety profile at 6 months and showed no serious adverse events related to the study treatment or injection procedure.